“uMotif is the only eCOA/ePRO company that started by working with patients to capture their health and well-being to share with their physicians. Today’s announcement underscores our unique ability to make it easier and more convenient for patients to participate in research.” -CEO Steve Rosenberg
BOSTON (PRWEB)
November 18, 2022
uMotif, one of the clinical trial technology market’s fastest growing companies, continues its transformation of the eCOA/DCT market with the announcement that its proprietary Motif data capture interface offers a validated alternative to text-based instruments for clinical, post-marketing and real-world research.
The industry-leading findings are the results of an independent quantitative equivalence study led by Willie Muehlhausen (SAFIRA Clinical Research), with testing undertaken at Dublin City University. Fifty-five participants completed testing in two randomized groups using the Motif interface and a traditional 5-point Verbal Response Scale (VRS-5). The study results showed equivalence between the Motif interface and a standard VRS (high ICC), demonstrating the Motif is an equivalent way of capturing VRS data. Equivalence testing was based on the most commonly used PROM – the EQ-5D-5L – which was provided for the study with support from Euroqol. Study results are expected to be published in 2023.
The Motif is a patented, flower-like graphical user interface. Each petal represents a different question, such as an Outcome Measure, symptom, or eDiary entry. Patients simply swipe on each petal to capture their data. The highly visual and easy-to-use interface is faster and more engaging for patients, which leads to higher rates of data capture compliance.
“Over the last 20 years the clinical research industry has standardized electronic presentation of traditional data capture widgets like the VRS, demonstrating equivalence to paper,” explained Willie Muehlhausen (LinkedIn) of SAFIRA Clinical Research. “The results from this study are exciting, as the Motif is the first new data capture interface since paper instruments were put onto a smartphone. This provides researchers with alternative ways of engaging patients to capture data through more visually appealing interfaces.”
Putting patients first is in uMotif’s DNA. The company’s experience over the past 10 years has proven that a patient centered approach is vital to delivering effective studies at pace and scale, with unrivaled patient engagement and volumes of quality data. uMotif studies including the Motif have engaged thousands of participants who have captured millions of data points which formed the basis for published research.
uMotif’s highly scalable eCOA/ePRO platform combines deep clinical knowledge and consumer design expertise to deliver unprecedented levels of patient compliance, regularly achieving >90% compliance in Real World studies. uMotif meets clinical and RWE market needs in any country, language, therapeutic area, and participant population, supporting site-based, hybrid, and fully virtual decentralized trials. Available on iOS, Android and the Web, the uMotif platform supports the most widely used eCOA/ePRO and eDiary input and evaluation types.
uMotif CEO Steve Rosenberg (LinkedIn) commented, “uMotif is the only eCOA/ePRO company that started by working with patients to capture their health and well-being to share with their physicians – unlike other companies that start with the protocol and push the questionnaires onto the patient. We help patients navigate and complete the study by capturing the necessary data at every point. Today’s announcement underscores our unique ability to make it easier and more convenient for patients to participate in research.”
About uMotif
The uMotif eCOA/ePRO platform delivers faster, quality clinical trials by putting participants at the core of research. uMotif’s configurable, modular and customizable eClinical cloud native platform powers site-based to fully decentralized clinical, real world, and post marketing research. For more information visit http://www.umotif.com
Share article on social media or email: